Laboratory of Experimental Pathophysiology, I.R.C.C.S. Saverio de Bellis, National Institute of Digestive Diseases, Castellana Grotte, Bari, Italy.
Aliment Pharmacol Ther. 2012 Feb;35(4):441-50. doi: 10.1111/j.1365-2036.2011.04970.x. Epub 2012 Jan 8.
The role of probiotics in the management of constipation is uncertain.
To evaluate the effects of probiotic-enriched artichokes on treatment preference, symptom profile and short-chain fatty acid (SCFA) production in constipated subjects when compared with ordinary artichokes.
Twenty constipated patients (3M/17F; 38.8 ± 14.4 years) were studied using a double-blind method and a computer-generated randomisation list. Each patient consumed 180 g per day of ordinary artichokes or artichokes enriched with Lactobacillus paracasei IMPC 2.1 for 15 days (daily dose of 2 × 10(10) CFU). Relief of symptoms was evaluated using a visual analogue scale. The stool consistency and symptom profile of patients were investigated using the Bristol stool form chart and the Gastrointestinal Symptom Rating Scale questionnaire (GSRS). SCFA production in faecal samples was evaluated using HPLC.
Eighty per cent of patients preferred probiotic-enriched artichokes to ordinary ones (P = 0.011). Satisfactory relief of symptoms was significantly higher (P = 0.0014) during the probiotic-enriched artichoke period. Bristol chart cluster scores were significantly higher (3.3 ± 1.2, 2.9 ± 1.3 2.2 ± 1.2, baseline, ordinary artichokes and probiotic-enriched ones, respectively; P = 0.009) and GSRS constipation was significantly lower (13.9 ± 0.9, 10.2 ± 0.8, 8.3 ± 0.9; P = 0.032) in the probiotic group compared with the baseline. As for SCFA production, propionic acid was significantly higher (2.2 ± 1.4, 2.1 ± 1.53, 1.5 ± 1.2; P = 0.035) in the probiotic group compared with baseline.
This trial shows a positive effect on symptoms in constipated patients after intake of probiotic-enriched artichokes.
益生菌在便秘治疗中的作用尚不确定。
评估富含益生菌的朝鲜蓟与普通朝鲜蓟相比,对便秘患者的治疗偏好、症状谱和短链脂肪酸(SCFA)产生的影响。
采用双盲法和计算机生成的随机分组表,对 20 例便秘患者(3M/17F;38.8±14.4 岁)进行研究。每位患者每天食用 180g 普通朝鲜蓟或富含副干酪乳杆菌 IMPC 2.1 的朝鲜蓟,持续 15 天(每日剂量为 2×10(10)CFU)。使用视觉模拟量表评估症状缓解情况。使用布里斯托粪便形态图表和胃肠道症状评分量表(GSRS)调查患者的粪便稠度和症状谱。使用 HPLC 评估粪便样本中 SCFA 的产生。
80%的患者更喜欢富含益生菌的朝鲜蓟(P=0.011)。富含益生菌的朝鲜蓟治疗期间,症状缓解满意度显著更高(P=0.0014)。布里斯托图表聚类评分显著更高(3.3±1.2、2.9±1.3、2.2±1.2,基线、普通朝鲜蓟和富含益生菌的朝鲜蓟,分别;P=0.009),GSRS 便秘显著更低(13.9±0.9、10.2±0.8、8.3±0.9;P=0.032)富含益生菌组与基线相比。就 SCFA 产生而言,丙酸在富含益生菌组中显著更高(2.2±1.4、2.1±1.53、1.5±1.2;P=0.035)与基线相比。
本试验显示,便秘患者摄入富含益生菌的朝鲜蓟后,症状有积极改善。